Antiangiogenic agents were developed against different targets and differ in their molecular structure and in their affinity and KM for the targets; bevacizumab inhibits VEGF-A [42] whereas nintedanib is a multitargeted tyrosine kinase (TKI) inhibitor that blocks several axes involved in the maintenance of an abnormal tumor stroma such as VEGFR1-4, PDGFRα and β, or FGFR1-3 [43]. Here, VEGFA is linked to neoplasm.